Which statement best describes considerations for using beta blockers in hypertension?

Which statement best describes considerations for using beta blockers in hypertension?

• A. Nonselective beta blockers are preferred for asthma due to bronchodilation.
• B. Cardioselective beta-1 blockers are preferred in asthma/COPD; nonselective agents can worsen bronchospasm; they can mask hypoglycemia and may affect lipid profiles; often added for CAD, arrhythmias, or heart failure with reduced ejection fraction.
• C. Beta blockers do not affect lipid profiles.
• D. They are never used in heart failure.

Answer: (B)

When using beta blockers for hypertension, the choice hinges on how these drugs interact with other conditions a patient may have—especially lung disease, diabetes, cholesterol, and heart conditions. Cardioselective beta-1 blockers target the heart more than the lungs, so they are preferred in people with asthma or COPD because they spare bronchial beta-2 receptors. In contrast, nonselective beta blockers block both beta-1 and beta-2 receptors, and beta-2 blockade in the airways can trigger or worsen bronchospasm, which is dangerous for asthma/COPD patients. Beta blockers can also mask the early signs of hypoglycemia, like rapid heartbeat, which is important for people with diabetes on insulin or certain oral agents. This masking effect can complicate diabetes management and requires careful monitoring. Additionally, beta blockers can influence lipid profiles, often associated with increases in triglycerides and decreases in HDL cholesterol, though the extent can vary by agent. Despite these considerations, beta blockers are frequently used alongside other diseases common with hypertension. They’re often added for coronary artery disease, certain heart rhythm problems, or heart failure with reduced ejection fraction, where they have proven benefits in outcomes and survival. The other statements fail to capture these nuances: nonselective blockers are not preferred in asthma for bronchodilation; beta blockers can affect lipids; and they are not never used in heart failure.

When using beta blockers for hypertension, the choice hinges on how these drugs interact with other conditions a patient may have—especially lung disease, diabetes, cholesterol, and heart conditions. Cardioselective beta-1 blockers target the heart more than the lungs, so they are preferred in people with asthma or COPD because they spare bronchial beta-2 receptors. In contrast, nonselective beta blockers block both beta-1 and beta-2 receptors, and beta-2 blockade in the airways can trigger or worsen bronchospasm, which is dangerous for asthma/COPD patients.

Beta blockers can also mask the early signs of hypoglycemia, like rapid heartbeat, which is important for people with diabetes on insulin or certain oral agents. This masking effect can complicate diabetes management and requires careful monitoring. Additionally, beta blockers can influence lipid profiles, often associated with increases in triglycerides and decreases in HDL cholesterol, though the extent can vary by agent.

Despite these considerations, beta blockers are frequently used alongside other diseases common with hypertension. They’re often added for coronary artery disease, certain heart rhythm problems, or heart failure with reduced ejection fraction, where they have proven benefits in outcomes and survival.

The other statements fail to capture these nuances: nonselective blockers are not preferred in asthma for bronchodilation; beta blockers can affect lipids; and they are not never used in heart failure.